R. Vera

发表

Hyperprogressive Disease: Main Features and Key Controversies

G. Kochan, D. Escors, H. Arasanz, 2021, International journal of molecular sciences.

Recommendations for follow-up of colorectal cancer survivors

J. Aparicio, F. Carballo, R. Vera, 2019, Clinical and Translational Oncology.

Omics Approaches in Pancreatic Adenocarcinoma

R. Zárate, J. Fernández-Irigoyen, E. Santamaría, 2019, Cancers.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

A. Carrato, F. López-Ríos, M. Salgado, 2016, Clinical and Translational Oncology.

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

M. Guillot, C. Pericay, J. Capdevila, 2022, Clinical and Translational Oncology.

SEOM Clinical Guideline of localized rectal cancer (2016)

E. Polo, J. Aparicio, C. Pericay, 2016, Clinical and Translational Oncology.

Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.

V. Arrazubi, R. Vera, F. Arias, 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

J. Maurel, F. Rivera, C. Grávalos, 2013, Clinical and Translational Oncology.

The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients

Maite Martínez, R. Vera, J. Arraras, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

G. Kochan, D. Escors, H. Arasanz, 2020, International journal of molecular sciences.

CAR-T Cells for the Treatment of Lung Cancer

J. Lasarte, G. Kochan, D. Escors, 2022, Life.

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

M. Guillot, C. Pericay, J. Capdevila, 2022, Clinical and Translational Oncology.

Local recurrence after five years is associated with preoperative chemoradiotherapy treatment in patients diagnosed with stage II and III rectal cancer.

G. Marín, R. Vera, A. Viúdez, 2017, International journal of surgery.

What is the Meaning of the Circumferential Resection Margin Involvement by Lymph Nodes Detected by Magnetic resonance?

R. Vera, F. Arias, G. Jiménez, 2020 .

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

C. García-Girón, J. Aparicio, J. Feliu, 2014, British Journal of Cancer.

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

M. Salgado, E. Aranda, E. Elez, 2020, Clinical and Translational Oncology.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

J. Aparicio, J. Feliu, D. Páez, 2018, Clinical and Translational Oncology.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

C. Pericay, C. Grávalos, E. Díaz-Rubio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

J. Feliu, M. Valladares-Ayerbes, R. Vera, 2017, Clinical and Translational Oncology.

Cancer Clinical Trials: Treatment Costs Associated With a Spanish National Health System Institution

R. Vera, A. Galbete, Ferran Capdevila, 2019, Therapeutic innovation & regulatory science.

Quality of Life in Spanish advanced non-small-cell lung cancer patients: determinants of global QL and survival analyses

Maite Martínez, R. Vera, J. Arraras, 2016, SpringerPlus.

Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.

R. Vera, A. Viúdez, F. Carvalho, 2016, Critical reviews in oncology/hematology.

Pathologic response of primary rectal cancer to oxaliplatin-based chemotherapy.

R. Vera, I. Amat, Marisa Gómez, 2011, Clinics in colon and rectal surgery.

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

R. García-Carbonero, M. Trapero-Bertran, J. Capdevila, 2019, Therapeutic advances in endocrinology and metabolism.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma

J. Baselga, E. Gallardo, A. Ribas, 1998, Cancer.

The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).

R. García-Carbonero, I. Matos, J. Capdevila, 2020, The oncologist.

Stent or surgery for incurable obstructive colorectal cancer: an individualized decisión

V. Arrazubi, R. Vera, J. Vila, 2009, International Journal of Colorectal Disease.

Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

J. Aparicio, A. Ferrández, R. Vera, 2017, Clinical and Translational Oncology.

Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

J. Aparicio, A. Ferrández, R. Vera, 2017, Clinical and Translational Oncology.

Understanding LAG-3 Signaling

G. Kochan, D. Escors, H. Arasanz, 2021, International journal of molecular sciences.

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Isabelle H. Osuch, Phillipa Bartlett, G. Kochan, 2021, British Journal of Cancer.

Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial

B. Bellosillo, C. Montagut, J. Maurel, 2021, Clinical Cancer Research.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

R. Jain, C. Montagut, J. Maurel, 2019, JAMA oncology.

Quality of life in long-term premenopausal early-stage breast cancer survivors from Spain. Effects of surgery and time since surgery.

R. Vera, K. Cambra, B. Ibáñez, 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

G. Kochan, D. Escors, H. Arasanz, 2022, Cells.

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.

J. Baselga, E. Gallardo, A. Ribas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

G. Kochan, D. Escors, H. Arasanz, 2018, Lung cancer management.

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

J. Fernández-Irigoyen, L. Mezquita, G. Kochan, 2022, Cancers.

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

M. Alsina, G. Kochan, D. Escors, 2022, Cancers.

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

J. Aparicio, J. Maurel, J. Capdevila, 2022, Clinical and Translational Oncology.

Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey †

C. Pericay, C. Grávalos, E. Díaz-Rubio, 2015 .

Impact of the COVID‐19 pandemic during Spain's state of emergency on the diagnosis of colorectal cancer

M. Ederra, R. Vera, J. Suárez, 2020, Journal of Surgical Oncology.

Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.

I. Arozarena, R. García-Carbonero, J. Capdevila, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

T. Macarulla, R. Vera, P. García-Alfonso, 2022, Clinical and Translational Oncology.

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

J. Tabernero, A. Grothey, R. Yaeger, 2020 .

Complications from the primary tumour are not related with survival in patients with synchronous stage IV colorectal cancer receiving chemotherapy without primary tumour resection

G. Marín, R. Vera, F. Oteiza, 2015, International Journal of Colorectal Disease.

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

G. Bodoky, J. Douillard, A. Awada, 2020, ESMO Open.

Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer.

J. Aparicio, C. Pericay, R. Vera, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

L. Vermeulen, C. Montagut, J. Maurel, 2020 .

RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.

M. Martín, C. Pericay, R. García-Carbonero, 2018 .

Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.

Gina Brown, J. Aparicio, J. Feliu, 2012 .

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer.

B. Perez-Villamil, E. Díaz-Rubio, E. Aranda, 2021, Cancer biomarkers : section A of Disease markers.

Clinical landscape of LAG-3-targeted therapy

G. Kochan, D. Escors, H. Arasanz, 2022, Immuno-oncology technology.

Spanish General Population Normative Data Analysis for the EORTC QLQ-C30 and Relationships Between Sex, Age, and Health Conditions

M. Rose, J. Giesinger, F. Efficace, 2021 .

Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study

V. Arrazubi, R. Vera, J. Arraras, 2019, Clinical and Translational Oncology.

Quality of life evolution in elderly survivors with localized breast cancer treated with radiotherapy over a three-year follow-up.

R. Vera, J. Arraras, A. Galbete, 2018, Breast.

An evaluation study of the determinants of future perspective and global Quality of Life in Spanish long-term premenopausal early-stage breast cancer survivors

R. Vera, J. Arraras, J. Illarramendi, 2016, Contemporary oncology.

R. Vera, J. Arraras, F. Arias de la Vega, 2011, Anales del sistema sanitario de Navarra.

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.

E. Gallardo, A. Ribas, J. Albanell, 1997, Acta oncologica.

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

G. Kochan, H. Kagamu, D. Escors, 2020, EMBO molecular medicine.

A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

Samuel J. Taylor, J. Kirkwood, J. Harris, 1985, Cancer research.

Cutting-Edge CAR Engineering: Beyond T Cells

G. Kochan, D. Escors, H. Arasanz, 2022, Biomedicines.

Radiologic and pathologic prognostic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.

C. Montagut, J. Aparicio, J. Feliu, 2015 .

Eyelid benign and malignant tumors: issues in classification, excision and reconstruction.

R. Vera, J. Suárez, R. Vera, 2013 .

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

C. Wellbrock, I. Arozarena, K. Breckpot, 2017, Cell reports.

Surgery for pancreatic ductal adenocarcinoma

A. Carrato, R. Vera, L. Díez, 2017, Clinical and Translational Oncology.

HUMAN PANCREATIC CANCER CELLS UNDERGO PROFOUND METABOLIC REPROGRAMMING TOWARDS CELLULAR STEMNESS AS ADAPTATION TO INHIBITION OF THE AKT PATHWAY

J. Fernández-Irigoyen, E. Santamaría, G. Kochan, 2020, bioRxiv.

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

E. Felip, R. Andrés, F. Rivera, 2016, Clinical and Translational Oncology.

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

G. Kochan, D. Escors, H. Arasanz, 2022, International journal of molecular sciences.

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

G. Kochan, D. Escors, H. Arasanz, 2020, Frontiers in Immunology.

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

G. Kochan, D. Escors, H. Arasanz, 2019, EMBO molecular medicine.

Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer

G. Kochan, D. Escors, H. Arasanz, 2018, bioRxiv.

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

G. Kochan, D. Escors, H. Arasanz, 2020, Frontiers in Pharmacology.

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

G. Kochan, D. Escors, H. Arasanz, 2020, Cancers.

Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial

V. Arrazubi, L. Teijeira, R. Vera, 2019, Annals of Surgical Oncology.

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

G. Kochan, D. Escors, H. Arasanz, 2020, International journal of molecular sciences.

The intracellular signalosome of PD-L1 in cancer cells

G. Kochan, D. Escors, H. Arasanz, 2018, Signal Transduction and Targeted Therapy.

Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma

J. Fernández-Irigoyen, E. Santamaría, J. Reyes, 2021, Frontiers in Medicine.

Current controversies in the management of metastatic colorectal cancer

M. Valladares-Ayerbes, F. Rivera, C. Pericay, 2015, Cancer Chemotherapy and Pharmacology.

A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma

P. Azcue, R. Vera, I. Encío, 2021, Cancers.

PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification

P. Azcue, R. Vera, I. Encío, 2021, Cancers.

Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

R. Salazar, E. Musulen, J. García-Foncillas, 2020, Clinical and Translational Oncology.

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

J. Feliu, J. Maurel, M. Salgado, 2016, Clinical and Translational Oncology.

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

J. Mayordomo, I. Tusquets, E. Alba, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. Rojo, E. de Álava, J. Rodríguez-Peralto, 2019, Clinical and Translational Oncology.

Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients.

E. Felip, R. Vera, J. D. Del Campo, 1997, American journal of clinical oncology.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study

J. Figueras, C. Montagut, J. Aparicio, 2020, Cancers.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

G. Kochan, D. Escors, H. Arasanz, 2019, International journal of molecular sciences.

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

A. Carrato, J. Feliu, R. García-Carbonero, 2021, Clinical and Translational Oncology.

Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer

L. Cerezo, T. Serrano, R. Vera, 2020, Clinical and Translational Oncology.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

E. Gallardo, M. Salgado, R. Pazo-Cid, 2018, BMC Cancer.

Stent placement prior to initiation of chemotherapy in patients with obstructive, nonoperative left sided tumors is associated with fewer stomas

G. Marín, R. Vera, J. Vila, 2017, Journal of surgical oncology.

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.

C. Montagut, J. Aparicio, J. Maurel, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d

S. Polo, J. Aparicio, J. Maurel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma

J. Feliu, J. Fernández-Irigoyen, J. Castaño, 2022, Cancers.

Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy

F. López-Ríos, R. Miquel, R. Vera, 2014, Clinical and Translational Oncology.

Quality of life in elderly patients with localized breast cancer treated with radiotherapy. A prospective study.

R. Vera, J. Arraras, J. Delfrade, 2016, Breast.

State of the Art: ctDNA in Upper Gastrointestinal Malignancies

V. Arrazubi, H. Arasanz, R. Vera, 2023, Cancers.

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients

R. Vera, M. Otero, J. Virizuela, 2018, Clinical and Translational Oncology.

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition

J. Fernández-Irigoyen, E. Santamaría, G. Kochan, 2020, Cancers.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

E. Gallardo, M. Salgado, R. Pazo-Cid, 2018, BMC Cancer.

Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI)

E. Gallardo, J. Albanell, J. Bellmunt, 1996, Tumori.

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

I. Melero, M. Rodriguez-Ruiz, F. Rotellar, 2018, Journal of Immunotherapy for Cancer.

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.

J. Carles, R. López-López, R. Mesía, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The EORTC quality of life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients

V. Arrazubi, L. Teijeira, R. Vera, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach

R. Vera, F. A. de la Peña, O. Juan-Vidal, 2023, Clinical and Translational Oncology.

Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus

Carrato, A. Carrato, L. Cerezo, 2021, Clinical and Translational Oncology.

Quality of life assessment by applying EORTC questionnaires to rectal cancer patients after surgery and neoadjuvant and adjuvant treatment.

R. Vera, J. Arraras, A. Viúdez, 2013, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

G. Kochan, D. Escors, H. Arasanz, 2019, Annals of Oncology.

General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition

S. Nolte, J. Giesinger, F. Efficace, 2021, Health and Quality of Life Outcomes.

Determinants of patient satisfaction with care in a Spanish oncology Day Hospital and its relationship with quality of life

Maite Martínez, R. Vera, J. Arraras, 2013, Psycho-oncology.

The cancer outpatient satisfaction with care questionnaire for chemotherapy, OUT-PATSAT35 CT: a validation study for Spanish patients

A. Brédart, Maite Martínez, R. Vera, 2012, Supportive Care in Cancer.

The EORTC cancer in-patient satisfaction with care questionnaire: EORTC IN-PATSAT32

Maite Martínez, R. Vera, J. Arraras, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

R. Salazar, J. Aparicio, R. García-Carbonero, 2015, Clinical and Translational Oncology.

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

E. Felip, P. Garrido, D. Isla, 2021, ESMO open.

Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.

C. Montagut, J. Aparicio, M. Martín, 2014, The oncologist.

Quality of life in Spanish postmenopausal breast cancer patients with localized disease who finish endocrine treatment: a prospective study

R. Vera, J. Arraras, J. Illarramendi, 2022, Menopause.

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.

A. Ribas, J. Albanell, J. Bellmunt, 1996, American journal of clinical oncology.

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

J. Bruix, J. Llovet, A. Forner, 2021, Medicina Clínica (English Edition).

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH.

J. Bruix, J. Llovet, A. Forner, 2021, Medicina clinica.

Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer

G. Kochan, D. Escors, H. Arasanz, 2018, bioRxiv.

Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM

C. Rubio, R. Vera, E. González-Flores, 2019, Clinical and Translational Oncology.

Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease‐free survival after preoperative radiochemotherapy for advanced rectal cancer

R. Vera, F Arias, F. Arias, 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.

R. Mesía, R. Vera, A. Berrocal, 2016, Oral oncology.

Chemoradiation of rectal cancer.

V. Arrazubi, R. Vera, J. Suárez, 2013, Minerva Chirurgica.

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

G. Kochan, D. Escors, H. Arasanz, 2019, EMBO molecular medicine.

Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

R. Vera, C. Labandeira, A. Montes, 2020, Clinical and Translational Oncology.

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

G. Kochan, D. Escors, H. Arasanz, 2023, International journal of molecular sciences.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

M. Hidalgo, F. Rivera, A. M. Muñoz Martín, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

Fernando Magno Quintão Pereira, C. Grávalos, E. Aranda, 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab

J. Figueras, R. Vera, I. Amat, 2014, Clinical and Translational Oncology.

Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

E. Felip, Á. Rodríguez-Lescure, P. Garrido, 2020, Clinical and Translational Oncology.

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer

F. Rivera, R. García-Carbonero, R. Vera, 2017, Clinical and Translational Oncology.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

J. Aparicio, J. Maurel, C. Grávalos, 2023, Clinical and Translational Oncology.

SEOM guidelines 2018

R. Vera, A. Santaballa, 2019, Clinical and Translational Oncology.

Aspirin, PIK3CA mutation, and colorectal-cancer survival.

R. Vera, A. Viúdez, Irene Hernández, 2013, The New England journal of medicine.

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer

J. Lasarte, L. Montuenga, R. Pio, 2023, EMBO reports.

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

J. Aparicio, J. Feliu, E. Casado, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

2017 SEOM guidelines: a multidisciplinary approach

R. Vera, A. Santaballa, 2018, Clinical and Translational Oncology.

Quality of life of early‐stage breast‐cancer patients diagnosed with COVID‐19 in the first three waves of the epidemic treated in the Spanish region of Navarre

L. Teijeira, R. Vera, J. Arraras, 2023, Psycho-oncology.

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab: Updated findings.

J. Figueras, R. Vera, A. Viúdez, 2012 .

Profiling of immune responses to COVID-19 and vaccination uncovers potent adjuvant capacities of SARS CoV-2 infection to vaccination leading to memory T cell responses with a Th17 signature in cancer patients

G. Kochan, D. Escors, H. Arasanz, 2022, medRxiv.

Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

F. Rivera, M. Salgado, C. Pericay, 2020, International Journal of Colorectal Disease.

Nab-paclitaxel: a flattering facelift.

M. Hidalgo, R. Vera, A. Viúdez, 2014, Critical reviews in oncology/hematology.

Abstract 930: CB213: A half-life extended bispecific Humabody VHdelivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+double-positive T cells

G. Kochan, D. Escors, H. Arasanz, 2020 .

Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group.

F. Rivera, M. Benavides, E. Aranda, 2014 .

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

J. Palacios, E. de Álava, X. Matías-Guiu, 2017, Clinical and Translational Oncology.

PD-1/LAG-3 DYSFUNCTIONALITY SIGNATURES IN HUMAN CANCERS

C. Johnston, J. Fernández-Irigoyen, G. Kochan, 2023, medRxiv.

Role of the next-generation immune checkpoint LAG-3 in response and resistance to cancer immunotherapy

G. Kochan, D. Escors, H. Arasanz, 2022, Proceedings of MOL2NET'22, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 8th ed. - MOL2NET: FROM MOLECULES TO NETWORKS.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

[Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology].

R. Salazar, E. Musulen, J. García-Foncillas, 2020, Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.

T. Macarulla, R. Vera, P. García-Alfonso, 2022, Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.